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Inflammatory bowel diseases (IBD), including ulcer-
ative colitis (UC) and Crohn’s colitis (CD), are character-
ized by chronic and recurrent inflammation of the gastro-
intestinal tract. Anti-tumor necrosis factor (TNF) agents 
proved to be effective and safe in IBD.1,2 However, there are 
still concerns about the risk of malignancy and infections 
after long-term use of anti-TNF agents.3,4 There have been 
few data regarding the discontinuation of anti-TNF agents 
in IBD patients who achieved remission. This paper pres-
ents a study that focuses on the discontinuation of anti-
TNF agents and evaluates risk factors in predicting relapse 
of the disease.
In the current issue, Song et al.5 conducted a retrospec-
tive, multicenter, uncontrolled study. They analyzed a total 
of 109 IBD patients (71 CD and 38 CD) treated with a first 
line anti-TNF agent (93 infliximab, 15 adalimumab, or one 
golimumab), and the median duration of the anti-TNF 
agent treatment was 12 months (range, 9.0 to 26.5 months). 
The cumulative relapse rates at 1, 2, 3, and 5 years for IBD 
patients were 17.4%, 32.9%, 46.7%, and 62.9%, respectively. 
The cumulative relapse rates for CD patients were 11.3%, 
31.4%, 46.7%, and 62.5%, and those for UC patients, were 
28.9%, 34.8%, 45.3%, and 60.9%, respectively.5 They sug-
gested discontinuation owing to patients’ preference (vs 
clinician’s decision) and adalimumab group (vs infliximab 
group) as risk factors of disease relapse in CD patients. The 
non-mucosal healing group (vs mucosal healing group) 
in UC was suggested to be a high-risk group of disease 
relapse. Despite its retrospective design, lack of therapeutic 
drug monitoring, and inadequate measurement of endo-
scopic parameters, this study appears to be meaningful be-
cause it is the first report about the discontinuation of anti-
TNF agents in the real-life clinical practice in Korea. 
Recently, Kobayashi et al.6 performed a first multicenter, 
open-labeled randomized controlled trial (RCT) in pa-
tients with UC treated with first line infliximab, and the 
median duration of infliximab treatment in discontinued 
infliximab group was 164.6 weeks. The median disease 
duration of discontinued infliximab group was 5.4 years. 
The cumulative relapse rates at 8, 16, 24, 32, 40, and 48 
weeks for UC patients were 6.5%, 23.9%, 26.1%, 32.6%, 
34.8%, and 45.7%, respectively. The relapse rates of UC in 
the study by Song et al. was relatively lower, approximately 
20%, compared to this RCT. The study population of in the 
study by Song et al. had a higher rate of ulcerative proctitis 
compared to the study by Kobayashi et al. (23.7% vs 2.0%). 
Also, the maintenance duration of anti-TNF in the study 
by Song et al. was relatively shorter compared to the study 
by Kobayashi et al. (48 weeks vs 164.6 weeks). The reasons 
for discontinuation of anti-TNF agents were various in 
real-life settings, which includes not only clinician’s deci-
sion but also patient’s preference. The relatively shorter 
maintenance duration of anti-TNF may indicate a lower 
inflammatory disease burden, which might have affected 
the outcomes. 
In terms of CD, Louis et al.7 performed a prospective, 
multicenter, uncontrolled trial with 125 patients treated 
with first line infliximab, and the median duration of inf-
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liximab treatment was 2.2 years. The median disease dura-
tion of discontinued infliximab group was 7.8 years. The 
cumulative relapse rates at 1 and 2 years were 43.9% and 
52.2%, respectively, which was also higher compared to the 
study by Song et al. The study population in the study by 
Song et al. had a lower rate of current smoking compared 
to the study by Louis et al. (7.0% vs 39.0%), which could 
affect the different relapse rates between the two studies. 
However, the baseline characteristics in the study by Song 
et al. was not better compared to the study by Louis et al. 
in terms of higher rates of ileum or ileo-colonic location 
of disease (70.4% vs 68%), stricturing behavior of disease 
(22.5% vs 10.0%), perianal disease (35.0% vs 59.2%), and 
previous history of intestinal surgery (25.4% vs 22.0%). 
The retrospective real-life study design might have affected 
the study outcomes and reduced relapse rates. 
The re-treatment with the same anti-TNF was effective 
in 96.1% (50/52 patients) in the study by Song et al. The 
poor response rate to the re-treatment was reported to be 
9% (4/46 patients) and 12% (5/43 patients) in the previous 
RCTs,6,7 which could be related to the immunogenicity of 
the anti-TNF agent. 
This study showed long-term outcomes after the discon-
tinuation of anti-TNF agents in Korea. However, careful 
consideration should be required before deciding the dis-
continuation of anti-TNFs, because of still its high rates of 
relapse and possible immunogenicity. Further prospective 
RCTs should be warranted for the discontinuation issue of 
anti-TNFs. Also, predicting factors including clinical, bio-
chemical, and molecular parameters should be determined 
to appropriately select patients who can discontinue the 
drug without future development of disease relapse.
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